The following is a summary of “Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial" published in the February 2023 issue of Diabetes and Endocrinology by Ray, et al. It is unknown if the siRNA therapy inclisiran,
More progress in prevention